Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes
The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil. Here, hepatitis B virus (HBV) DNA positivity, drug resistance mutations and their association with HBV genotypes were evaluated in chronically HBV-infected patients under different drug regimens in Br...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fundação Oswaldo Cruz (FIOCRUZ)
2012-05-01
|
| Series: | Memorias do Instituto Oswaldo Cruz |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000300005&lng=en&tlng=en |
| _version_ | 1797756898887335936 |
|---|---|
| author | Francisco Campello do Amaral Mello Carlos Augusto Fernandes Selma de Andrade Gomes |
| author_facet | Francisco Campello do Amaral Mello Carlos Augusto Fernandes Selma de Andrade Gomes |
| author_sort | Francisco Campello do Amaral Mello |
| collection | DOAJ |
| description | The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil. Here, hepatitis B virus (HBV) DNA positivity, drug resistance mutations and their association with HBV genotypes were evaluated in chronically HBV-infected patients under different drug regimens in Brazil. The study involved 129 patients under interferon or nucleos(t)ide analogue therapy for a median treatment time of 12 months. One hundred and five (81%) of these patients were treated with lamivudine (LAM), either in monotherapy or in combination with newer drugs, such as entecavir (ETV) or tenofovir (TDF). High (37.5-100%) rates of HBV DNA positivity were observed with all but one drug regimen (LAM + ETV). However, patients that were treated with ETV alone, TDF alone or with LAM combination therapies had a mean viral load that was 3-4 log lower than patients treated with LAM monotherapy. Of the patients treated with LAM, 47% developed resistance mutations. HBV genotypes A (59.1%), D (30.3%) and F (9.1%) were found. There was no association between the presence of LAM resistance mutations and genotypes, HBeAg status or treatment duration. Nevertheless, the rtM204V mutation was observed more frequently (12/13, 92%) in genotype A than in the others (p = 0.023). Six out of nine isolates that contained the rtM204I mutation belonged to genotype D and half of them displayed a single mutation. Genotype D isolates with the rtM204V variant preferentially displayed a triple mutation, while genotype A preferentially displayed a double mutation (p = 0.04). |
| first_indexed | 2024-03-12T18:07:11Z |
| format | Article |
| id | doaj.art-2a62cb8e33cb43358584465aee39f988 |
| institution | Directory Open Access Journal |
| issn | 1678-8060 |
| language | English |
| last_indexed | 2024-03-12T18:07:11Z |
| publishDate | 2012-05-01 |
| publisher | Fundação Oswaldo Cruz (FIOCRUZ) |
| record_format | Article |
| series | Memorias do Instituto Oswaldo Cruz |
| spelling | doaj.art-2a62cb8e33cb43358584465aee39f9882023-08-02T09:25:55ZengFundação Oswaldo Cruz (FIOCRUZ)Memorias do Instituto Oswaldo Cruz1678-80602012-05-01107331732510.1590/S0074-02762012000300005S0074-02762012000300005Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypesFrancisco Campello do Amaral Mello0Carlos Augusto Fernandes1Selma de Andrade Gomes2Fundação Oswaldo CruzLaboratório Central de Saúde Pública Noel NutelsFundação Oswaldo CruzThe effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil. Here, hepatitis B virus (HBV) DNA positivity, drug resistance mutations and their association with HBV genotypes were evaluated in chronically HBV-infected patients under different drug regimens in Brazil. The study involved 129 patients under interferon or nucleos(t)ide analogue therapy for a median treatment time of 12 months. One hundred and five (81%) of these patients were treated with lamivudine (LAM), either in monotherapy or in combination with newer drugs, such as entecavir (ETV) or tenofovir (TDF). High (37.5-100%) rates of HBV DNA positivity were observed with all but one drug regimen (LAM + ETV). However, patients that were treated with ETV alone, TDF alone or with LAM combination therapies had a mean viral load that was 3-4 log lower than patients treated with LAM monotherapy. Of the patients treated with LAM, 47% developed resistance mutations. HBV genotypes A (59.1%), D (30.3%) and F (9.1%) were found. There was no association between the presence of LAM resistance mutations and genotypes, HBeAg status or treatment duration. Nevertheless, the rtM204V mutation was observed more frequently (12/13, 92%) in genotype A than in the others (p = 0.023). Six out of nine isolates that contained the rtM204I mutation belonged to genotype D and half of them displayed a single mutation. Genotype D isolates with the rtM204V variant preferentially displayed a triple mutation, while genotype A preferentially displayed a double mutation (p = 0.04).http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000300005&lng=en&tlng=enHBVtherapylamivudineantiviral drug resistance |
| spellingShingle | Francisco Campello do Amaral Mello Carlos Augusto Fernandes Selma de Andrade Gomes Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes Memorias do Instituto Oswaldo Cruz HBV therapy lamivudine antiviral drug resistance |
| title | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes |
| title_full | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes |
| title_fullStr | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes |
| title_full_unstemmed | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes |
| title_short | Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes |
| title_sort | antiviral therapy against chronic hepatitis b in brazil high rates of lamivudine resistance mutations and correlation with hbv genotypes |
| topic | HBV therapy lamivudine antiviral drug resistance |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000300005&lng=en&tlng=en |
| work_keys_str_mv | AT franciscocampellodoamaralmello antiviraltherapyagainstchronichepatitisbinbrazilhighratesoflamivudineresistancemutationsandcorrelationwithhbvgenotypes AT carlosaugustofernandes antiviraltherapyagainstchronichepatitisbinbrazilhighratesoflamivudineresistancemutationsandcorrelationwithhbvgenotypes AT selmadeandradegomes antiviraltherapyagainstchronichepatitisbinbrazilhighratesoflamivudineresistancemutationsandcorrelationwithhbvgenotypes |